Success Metrics

Clinical Success Rate
73.5%

Based on 25 completed trials

Completion Rate
74%(25/34)
Active Trials
9(17%)
Results Posted
44%(11 trials)
Terminated
9(17%)

Phase Distribution

Ph phase_3
10
19%
Ph not_applicable
6
11%
Ph phase_1
5
9%
Ph phase_2
9
17%
Ph phase_4
14
26%

Phase Distribution

5

Early Stage

9

Mid Stage

24

Late Stage

Phase Distribution44 total trials
Phase 1Safety & dosage
5(11.4%)
Phase 2Efficacy & side effects
9(20.5%)
Phase 3Large-scale testing
10(22.7%)
Phase 4Post-market surveillance
14(31.8%)
N/ANon-phased studies
6(13.6%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

67.6%

25 of 37 finished

Non-Completion Rate

32.4%

12 ended early

Currently Active

9

trials recruiting

Total Trials

53

all time

Status Distribution
Active(10)
Completed(25)
Terminated(12)
Other(6)

Detailed Status

Completed25
Terminated9
Recruiting8
unknown5
Withdrawn3
Suspended1

Development Timeline

Analytics

Development Status

Total Trials
53
Active
9
Success Rate
73.5%
Most Advanced
Phase 4

Trials by Phase

Phase 15 (11.4%)
Phase 29 (20.5%)
Phase 310 (22.7%)
Phase 414 (31.8%)
N/A6 (13.6%)

Trials by Status

terminated917%
suspended12%
active_not_recruiting12%
not_yet_recruiting12%
unknown59%
withdrawn36%
recruiting815%
completed2547%

Recent Activity

Clinical Trials (53)

Showing 20 of 53 trialsScroll for more
NCT05943223Phase 2

Piperacillin/Tazobactam Versus ceftriAxone and Metronidazole for Children With Perforated Appendicitis (ALPACA)

Completed
NCT07620223Not Applicable

Prophylactic Antibiotics in Preventing Surgical Site Infection After Hepatobiliary Surgery in High-Resistant Settings

Recruiting
NCT04276480Not Applicable

Efficacy of Piperacillin-tazobactam as Empirical Antimicrobial Therapy for VAP Among ESBL-E Carriers.

Completed
NCT06712641Phase 4

Aminoglycosides in Early Sepsis

Recruiting
NCT03078010Phase 2

Choosing the Best Antibiotic to Protect Friendly Gut Bacteria During the Course of Stem Cell Transplant

Active Not Recruiting
NCT06954129Phase 4

A Pragmatic Clinical Trial Comparing the Risk of Acute Kidney Injury During Treatment With Vancomycin and Piperacillin-Tazobactam vs. Vancomycin and Cefepime in Hospitalized Patients

Recruiting
NCT06426836Not Applicable

Pediatric Antibiotic Dosing in Extracorporal Membrane Oxygenation (PADECMO)

Recruiting
NCT03269994Phase 3

Does Cefoxitin or Piperacillin-Tazobactam Prevent Postoperative Surgical Site Infections After Pancreatoduodenectomy?

Completed
NCT03671967Phase 4

PipEracillin Tazobactam Versus mERoPENem for Treatment of Bloodstream Infections Caused by Cephalosporin-resistant Enterobacteriaceae (PETERPEN)

Recruiting
NCT06184659Phase 4

Empirical Meropenem Versus Piperacillin/Tazobactam for Adult Patients With Sepsis

Recruiting
NCT06977347Not Applicable

Appropriateness of Antibiotic Combination Therapy for Severe Community-acquired Pneumonia in South Korea

Not Yet Recruiting
NCT02820987Phase 3

PK/PD of Extended-infusion Meropenem, Piperacillin-tazobactam and Cefepime in the Early Phase of Septic Shock

Completed
NCT04983901Phase 2

PHASE II SINGLE-CENTER, RANDOMIZED, OPEN-LABEL, PROSPECTIVE, STUDY TO DETERMINE THE IMPACT OF SERIAL PROCALCITONIN

Completed
NCT05753735Phase 2

eXtended Antibiotic Prophylaxis for Intermediate- and High-risk Glands After Pancreatoduodenectomy to Reduce CR-POPF

Terminated
NCT02735707Phase 3

Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

Recruiting
NCT06422533Not Applicable

Ceftolozane/Tazobactam vs. Piperacillin/Tazobactam for the Treatment of Bacteremia in Hemato-oncological Patients

Recruiting
NCT05981079Phase 4

Model-based Dose Versus Empirical Dose of Piperacillin/Tazobactam in Preterm Neonates With Late-onset Sepsis.

Unknown
NCT03262142Phase 4

Targeted AntiBiotics for Chronic Pulmonary Diseases

Terminated
NCT04394182Not Applicable

Ultra Low Doses of Therapy With Radiation Applicated to COVID-19

Suspended
NCT03922451

Pharmacokinetics of Antibiotics During Extracorporeal Membrane Oxygenation (ECMO) Support

Terminated

Drug Details

Intervention Type
DRUG
Total Trials
53